In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DJ Pharma Inc.

Division of Bausch Health Companies Inc./Biovail Corp.

Latest From DJ Pharma Inc.

Big Biotech Emerges as Late-Stage Licensee

The sheer size of today's Big Pharmas has created a problem when it comes to licensing late-stage products; many of those available simply don't have large enough revenue projections to significantly contribute to the Big Pharmas' earnings. But larger biotechs, which don't necessarily need blockbusters to grow earnings, seem to have begun to fill the gap.
BioPharmaceutical Business Strategies

Q & A on Reverse Licensing

An increasing amount of funding appears to be going to start-ups that in-license compounds from pharma companies in agreements known as reverse licensings. Some of the key points in structuring such a deal are: 1) defining the "licensed compound"; ensuring access to data and people; freedom to develop the compound in an unencumbered manner; buyback rights ;constructing sensible economics; and controlling the intellectual property.
BioPharmaceutical Strategy

Andrx's New-Style Generics

Andrx is at the forefront of a new breed of generics companies: diversified, entrepreneurial, litigious, and competent at handling complex science. In the mid-1990s, when the last big wave of patent expirations created huge opportunities for generics, the industry responded with debilitating price wars, conniving tactics to tie up raw material supplies, and too many me-too drugs. These days are gone. Industry consolidation has weeded out weaker players, helping to stabilize pricing and increase resources, and generics companies are far more sophisticated and diversified than in the past. Andrx picked up early on trends in the industry--its founders saw a gap in generic distribution that others didn't see, and set up a generic drug distribution business to service independent pharmacies. It was among the first to realize that one way to avoid price wars would be to focus on hard-to-manufacture products using innovative technologies to avoid infringing patents. It has from its inception emphasized diversification, positioning itself as a drug delivery company that can apply its proprietary technologies to both generics and branded products. It is evolving into branded products, first by in-licensing niche, undermarketed drugs from big pharma companies, and then by developing improved versions of branded drugs that are about to go off patent. But being a drug delivery company is tough, and Andrx has yet to prove that it has both a creative enough drug delivery technology and the marketing savvy to be a success at it.
BioPharmaceutical Strategy

Dealmaking Along the Faultlines

Big Pharma's valuations are depressed; biotech is red-hot. Alliance volumes have fallen, but average deal values are up. The valuation divide masks the subtler cracks dividing biotech's elite from a mass of undifferentiated technology providers. Drug companies are recognizing that basing discovery programs around new, proprietary targets is highly risky and lengthens R&D time. Targets themselves, absent optimized lead compounds, are increasingly commoditized. Therefore, companies who don't provide integrated discovery capabilities aren't going to get the high-value deals that will justify their current, sky-high valuations. Meanwhile, companies with integrated solutions must back up their promises of productivity enhancement with their own money--though they also get a richer share of the end proceeds.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Bausch Health Companies Inc.
  • Valeant Pharmaceuticals International
  • Senior Management
  • James W Newman, Pres. & CEO
    Jerry E Canning, VP, Fin.
    David Preston, VP, Sales & Mktg.
  • Contact Info
  • DJ Pharma Inc.
    Phone: (877) 357-4276
    12730 High Bluff Dr.
    Ste. 160
    San Diego, CA 92130